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S U M M A R Y
Objectives: To determine the risk factors for community-acquired pneumonia (CAP) with inﬂuenza A/
H1N1 ﬂu in our region.
Methods: Adult patients with CAP from July 2009 to February 2010 who were screened for inﬂuenza A/
H1N1 were identiﬁed retrospectively. This was a retrospective case–control study. Cases had CAP with
inﬂuenza A/H1N1 and controls had CAP without inﬂuenza A/H1N1. Patient ﬁles were reviewed for
demographics, clinical characteristics, treatment, and outcome.
Results: Three hundred and eight patients with CAP were identiﬁed: 107 cases and 201 controls. For cases
vs. controls there were signiﬁcant differences in the following: median age (40 (range 18–82) vs. 56
(range 18–89) years; p < 0.001), female gender (63.6% vs. 44.3%; p < 0.05), Bedouin Arab origin (41.1% vs.
26.4%; p < 0.05), pyrexia (97.6% vs. 88.5%; p < 0.01), cough (96.3% vs. 75%; p < 0.05), admission to the
intensive care unit (18.7% vs. 10.6%; p < 0.05), and CURB-65 score 3 (2.8% vs. 11.4%; p < 0.05).
Laboratory values including white blood cell (WBC) and platelet counts were lower in cases than in
controls, whereas creatine phosphokinase and lactate dehydrogenase levels were higher (p < 0.01). By
logistic regression models, young age, Bedouin origin, and lower WBC and platelet counts were
independent risk factors for the acquisition of CAP with inﬂuenza A/H1N1.
Conclusions: In our region CAP with inﬂuenza A/H1N1 occurred in younger females of Bedouin Arab
origin with less co-morbidity. No difference in mortality was found. We believe that inequalities in
socioeconomic conditions could explain our ﬁndings.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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April 2009 marked the beginning of the 2009 inﬂuenza A/H1N1
pandemic (2009 H1N1). It is estimated that approximately 43–89
million persons in the USA became ill with 2009 H1N1 between
April 2009 and April 2010.1 As at August 2010, more than 214
countries and overseas territories or communities had reported
laboratory-conﬁrmed cases of 2009 H1N1, including 18 449
deaths.2 This ﬂu can be associated with severe illness and death in
young, previously healthy individuals. At least 5% of patients with
conﬁrmed 2009 H1N1 infections have been found to develop
pneumonia.3 Symptoms such as dyspnea, wheezing, vomiting, and§ This work was presented in part at the 50th Interscience Conference on
Antimicrobial Agents and Chemotherapy (Abstract L1-1034), Boston, MA, USA,
September 12–15, 2010.
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doi:10.1016/j.ijid.2011.03.015diarrhea are associated with pneumonia resulting from pandemic
H1N1 infection.3 2009 H1N1 pneumonia has been associated with
prolonged hospital admission, increased intensive care unit (ICU)
admission, and increased disability compared to non-pneumonia
2009 H1N1.4 Severe community-acquired pneumonia (CAP) has
been described among young adults with 2009 H1N1, attributed to
delayed initiation of antiviral therapy.5
Well-known risk factors for the acquisition of 2009 H1N1 have
been described, but risk factors for CAP with 2009 H1N1 are less
known. Our aim was to determine the risk factors for CAP with
inﬂuenza A/H1N1 ﬂu in our region.
2. Materials and methods
2.1. Subjects
The study was performed at Soroka University Medical Center, a
1000-bed tertiary-care teaching hospital, serving more than 500
000 inhabitants in southern Israel. Our region can be characterizedses. Published by Elsevier Ltd. All rights reserved.
Table 1
Detection of respiratory viruses
Viral set Primers and probe sequence Concentration (nM)
H1N1 (Ref. 6) H1-Ger SW-F cat ttg aaa ggt ttg aga tat tcc c 400
H1-Ger SW-R atg ctg ccg tta cac ctt tgt 400
H1-Ger SW-P Cy-5-aca agt tca tgg ccc aat cat gac tcg-BBQ 200
Inﬂuenza A universal Inf-A-F (CDC) gac cra tcc tgt cac ctc tga c 300
Inf-A-R (CDC) agg gca tty tgg aca aak cgt cta 300
Inf-A-P (CDC) FAM-tgc agt cct cgc tca ctg ggc acg-BHQ 200
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population with a minority of Bedouin Arabs, and a surrounding
large arid Negev desert area where a nomad population of mostly
Bedouin Arabs live. We retrospectively identiﬁed all adults who
presented to our emergency room with inﬂuenza-like illness (ILI)
and who were screened for inﬂuenza A/H1N1 during the study
period of July 2009 through February 2010, from the records of the
Virology Laboratory. We then divided these hospitalized patients
with pneumonia into cases and controls. Cases were deﬁned as any
patient aged 18 years hospitalized with pneumonia who tested
positive for inﬂuenza A/H1N1. Controls were deﬁned as any
patient aged 18 years hospitalized with pneumonia who tested
negative for inﬂuenza A/H1N1.
2.2. Measures
Data were collected using a pre-designed structured ques-
tionnaire covering demographic background including age,
gender, origin, ward in which they were hospitalized, pregnan-
cy, smoking, body mass index (BMI), CURB-65 score, Charlson
co-morbidity index, and underlying diseases. The CURB-65
criteria were dichotomized into high (3, indicating higher risk
of death) and low (2, indicating lower risk of death). The
presence of symptoms of respiratory infection (ILI) and
gastrointestinal complaints, as well as relevant laboratory data
such as complete blood count, renal function tests, liver
enzymes, creatine phosphokinase (CPK), lactate dehydrogenase
(LDH), blood gases, and sputum and blood cultures were noted.
Chest X-ray results, antiviral and antibiotic treatment, length of
in-hospital stay, end of hospitalization, and 30-day mortality
were also recorded.
2.3. Sampling
All patients presenting to our emergency room with ILI were
tested for inﬂuenza A/H1N1. The samples were taken as close as
possible to the time of hospital admission and in no case more than
24 h later. Three consecutive samples were taken from each
participant: one oropharyngeal swab and two nasopharyngeal
swabs, using swab applicators (Virocult Sigma 3, Medical Wire &
Equipment, UK).
After sampling, the nasopharyngeal and oropharyngeal swab
applicators were cut and placed together in one tube containingTable 2
Demographic characteristics of the patient population, cases vs. controls
Variable Cases (n = 107) 
Age (median) 40 (18–82) 
Female gender 68 (63.6%) 
Origin
Bedouin Arab 44 (41.1%) 
Residence 
Home 105 (98.1%) 
Nursing-home 2 (1.9%) 
Smoker 19 (17.8%) 
OR, odds ratio; CI, conﬁdence interval.3.0 ml of RPMI solution (Biological Industries, Beit Haaemek,
Israel). The test tube with the swabs was vortexed for 5 min, after
which the head of the applicator was drained against the sides of
the test tubes and then removed. Nucleic acid extraction was
performed using NucliSENS easyMAG (bioMe´rieux, Marcy l’Etoile,
France), according to the manufacturer’s instructions. A quantity of
400 ml was extracted into 50 ml of elution solution.
2.4. Detection of respiratory viruses
Each sample was tested in parallel in one test tube for the
following viruses: inﬂuenza A and inﬂuenza A H1N1. The sets of
primers and probes used to detect the two viruses by multiplex
hydrolysis probes-based real-time polymerase chain reaction
(mqRT-PCR) are shown in Table 1.6
2.5. Pneumonia
CAP was diagnosed based on clinical features and a chest X-ray.
All chest X-rays were reviewed by a radiologist who conﬁrmed the
diagnosis.
2.6. Statistical analysis
The sample size (conﬁdence interval 95%, power 80%) was
calculated using Epi Info version 4.3.4 software (CDC, Atlanta, GA,
USA). For categorical variables, proportions were compared using
Fisher’s exact test or the Chi-square test, as appropriate.
Continuous variables were analyzed with the Student’s t-test or
the Wilcoxon rank sum test, depending on the validity of the
normality assumption. A two-tailed p-value of < 0.05 was
considered signiﬁcant. Multivariate analysis was performed using
logistic regression. A signiﬁcance level of <0.05 was used in this
test. All analyses were performed using SPSS version 15 (IBM SPSS,
Chicago, IL, USA).
3. Results
Three hundred and eight patients with CAP were identiﬁed: 107
cases and 201 controls. Cases were signiﬁcantly younger, of female
gender, and of Bedouin Arab origin (Table 2) than controls.
On the other hand, controls had a signiﬁcantly higher rate of co-
morbidities compared to cases, including smoking, diabetes,Controls (n = 201) p-Value, OR (95% CI)
56 (18–89) <0.001
89 (44.3%) 0.002, 2.19 (1.35–3.5)




64 (33.7%) 0.011, 0.46 (0.24–0.76)
Table 3
Underlying diseases, cases vs. controls
Variable Cases (n = 107) Controls (n = 201) p-Value (95% CI)
Pregnancy 15/68 (22.1%) 7/89 (7.9%) 0.01 (1.17–9.7)
Peripartum 5/68 (7.4%) 6/89 (6.7%) 0.747
Obesity 31 (29.0%) 41 (22.5%) 0.26
Chronic lung disease 20 (18.7%) 45 (22.4%) 0.27
Diabetes 17 (15.9%) 53 (26.4%) 0.045 (0.29–0.967)
Cardiovascular diseases 2 (1.9%) 38 (18.9%) <0.001 (0.02–0.35)
Congestive heart failure 6 (5.6%) 28 (13.9%) 0.034 (0.15–0.91)
Chronic renal failurea 4 (3.7%) 22 (10.9%) 0.032 (0.106–0.94)
Peripheral vascular disease 1 (0.9%) 5 (2.5%) 0.68
CVA/TIA 5 (4.7%) 14 (7.0%) 0.62
Liver disease 4 (3.7%) 4 (2.0%) 0.45
Malignancy 10 (9.3%) 23 (11.4%) 0.57
Organic brain syndrome 6 (5.6%) 27 (13.4%) 0.03 (0.17–0.92)
CI, conﬁdence interval; CVA, cerebrovascular accident; TIA, transient ischemic attack.
a Creatinine >2 mg/dl.
Figure 1. Clinical characteristics of patients with CAP (*p-value = non-signiﬁcant;
GI = gastrointestinal symptoms; ICU = admissions to the intensive care unit;
MV = mechanical ventilation).
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failure, and cardiovascular disease (Table 3). Chronic lung disease,
obesity, and the pregnancy rate were similar in both groups
(p = not signiﬁcant).Table 4
Laboratory values, cases vs. controls
Variable Cases 
Hemoglobin g/dl, mean ( SD) 12.4  1.9 
WBC  109/l, mean ( SD) 8.703  6.499 
PMN  109/l, mean ( SD) 6.958  5.453 
Lymphocytes  109/l, mean ( SD) 1.312  2.027 
PLT  109/l, mean ( SD) 202.514  92.231 
Glucose mg/dl, median (range) 109 (40–525) 
Urea mg/dl, median (range) 27 (5–190) 
Creatinine mg/dl, median (range) 0.73 (0.2–7.3) 
Sodium mEq/l, median (range) 136 (120–143) 
CPK U/l, median (range) 120 (26–7346) 
LDH U/l, median (range) 558 (323–1951) 
SGPT U/l, median (range) 22 (7–245) 
SGOT U/l, median (range) 29 (9–306) 
Positive blood cultures,a n (%) 1 (1.1%) 
Positive sputum cultures,b n (%) 0 (0%) 
SD, standard deviation; WBC, white blood cells; PMN, polymorphonuclear neutrophils; PL
glutamic pyruvic transaminase; SGOT, serum glutamic oxaloacetic transaminase.
a Blood cultures in cases were positive for: Escherichia coli (1); blood cultures in 
pneumoniae (3), Escherichia coli (1), Propionibacterium granulosum (1), Micrococcus (1).
b Sputum cultures in controls (some grew more than one pathogen) were positive for
pneumoniae (2), group B Streptococcus (1), Enterococcus spp (1), methicillin-sensitive St
negative Staphylococcus (1), Haemophilus inﬂuenzae (3), Pseudomonas aeruginosa (7), SPatient clinical characteristics at hospital admission are
presented in Figure 1. Among the cases there was a greater
proportion of patients with pyrexia (>38 8C) (odds ratio (OR) 4.5,
95% conﬁdence interval (CI) 1.32–15.37, p = 0.006), cough (OR 8.58,
95% CI 3.0–24.5, p < 0.0001), and CURB-65 score of 2 (OR 4.48,
95% CI 1.24–19.22, p = 0.017).
Table 4 summarizes the laboratory ﬁndings. In cases vs.
controls, laboratory values including white blood cell (WBC),
polymorphonuclear neutrophil (PMN) and platelet counts, and
urea and creatinine levels were lower, whereas CPK and LDH
levels were signiﬁcantly higher (p < 0.01). Bacteremia was
found in 9.9% of controls vs. 1.1% of cases (p < 0.01). Chest X-
rays showing unilateral inﬁltrates were the most frequent
ﬁnding: 79% in cases vs. 71% in controls (p = not signiﬁcant).
Prompt antibiotic treatment was initiated for all cases and
controls and antiviral treatment (oseltamivir) was initiated in all
cases. With regard to ICU admission, 18.7% of cases were admitted
to the ICU vs. 10.6% of the control group (p < 0.05). The number of
patients requiring mechanical ventilation was 15% vs. 9.3%, the
mean length of hospitalization was 4 days (range 1–45) vs. 3 days
(range 1–55), and the in-hospital crude mortality rate was 8.5% vs.
6.6%, in the case and control groups, respectively (all p = not
signiﬁcant).Controls p-Value
12.9  7.5 0.471
11.791  6.821 <0.001
9.881  7.472 <0.001
1.348  0.988 0.833











T, platelets; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; SGPT, serum
controls were positive for: coagulase-negative Staphylococcus (8), Streptococcus
: Candida albicans (10), non-albicans Candida (6), Aspergillus ﬂavus (1), Streptococcus
aphylococcus aureus (2), methicillin-resistant Staphylococcus aureus (1), coagulase-
tenotrophomonas maltophilia (3), Enterobacter spp (3), Klebsiella spp (2).
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Bedouin origin (95% CI 1.031–8.615), and lower WBC (95% CI 1.32–
1.980) and platelet (95% CI 1.103–1.980) counts were independent
risk factors for CAP with inﬂuenza A/H1N1.
4. Discussion
Pneumonia has been found in 5–29% of adult patients
hospitalized with laboratory-conﬁrmed 2009 inﬂuenza A/H1N1,
and in up to 40% in a mixed cohort of pediatric and adult
patients.3,7–9
Clinical features independently associated with pneumonia in
patients with this pandemic ﬂu include dyspnea, wheezing,
vomiting, and diarrhea.3 Studies have further shown that antiviral
therapy started at >48 h after the onset of symptoms tends to be
more common in patients with pneumonia or other inﬂuenza
complications than in those without.3,10
Nguyen-Van-Tam et al. described risk factors for a severe
outcome in patients hospitalized with pandemic inﬂuenza A/
H1N1; an abnormal chest X-ray or a raised C-reactive protein
level, especially in patients recorded as obese or in those with
pulmonary conditions other than asthma or chronic obstructive
pulmonary disease, indicated a potentially serious outcome.7
Mulrennan et al. concluded that the CURB-65 score does not
predict severe 2009 pandemic inﬂuenza A/H1N1 CAP or the need
for ICU admission.4
Non-speciﬁc laboratory tests have been researched as
indicators of severity of pandemic H1N1 with pneumonia.
Cunha et al. showed that while the presence of otherwise
unexplained relative lymphopenia and thrombocytopenia were
key diagnostic markers for hospitalized adults with pandemic
inﬂuenza A/H1N1 pneumonia, their degree and duration did not
predict clinical severity. They also noted an elevated CPK level,
which likewise was not found to predict clinical severity or
adverse outcomes.11
In our patient population, we found young age, Bedouin Arab
origin, and lower WBC and platelet counts to be independent risk
factors for the acquisition of CAP with inﬂuenza A/H1N1.
A higher incidence of CAP hospitalizations has previously
been found in adult Bedouin Arabs compared to the adult Jewish
population in southern Israel, although no difference was
demonstrated in the clinical outcomes.12 In comparison,
Bedouin Arab children have been shown to be at a higher risk
of hospitalization for infectious diseases (diarrhea and pneumo-
nia) in early childhood as compared to Jewish children.13 In
Bedouin Arab children with CAP, a more severe clinical course
and a higher rate of morbidity than in Jewish children has been
demonstrated.14 Different socioeconomic factors (e.g., a very
high birth rate, crowded living conditions, low income) could
explain the higher rate of CAP in Bedouin Arabs living in
southern Israel. 2009 H1N1 has been investigated in ethnic
minority groups worldwide, showing higher attack rates and a
worse prognosis in these populations. The ﬁrst wave of the 2009
H1N1 pandemic in Wisconsin USA disproportionately affected
hospitalized patients who were African Americans, Asians, and
Hispanics compared to non-Hispanic whites.15 Indigenous
populations from Australia, Canada, and New Zealand have
been found to have a three to six times higher rate of
hospitalization and death associated with infection with the
2009 H1N1 virus.16 In England, mortality rates were found to be
higher for Bangladeshi and Pakistani children than for white
British children.17
Previous studies have reported 7–14.7% mortality in patients
with pneumonia and inﬂuenza A/H1N1.18,19 Independent risk
factors for death are progressive dyspnea after resolution of
fever and a higher APACHE II (acute physiology and chronichealth evaluation) score on presentation.18 Cui et al. found an
association between obesity and lymphopenia that was not
restored after 5 days of treatment, and a poor outcome in
hospitalized pneumonia patients with 2009 pandemic H1N1.19
The outcome of our CAP patients, cases and controls, was
similar, with 8.5% and 6.6% mortality, respectively (p = not
signiﬁcant). Possible explanations for the relatively favorable
clinical outcome in our patients include: patients of a young age,
low co-morbidity rate, accessible rapid diagnostic tests (RT-
PCR), and early administration of oseltamivir and antibiotic
treatment. In comparison to other studies, we included only
patients presenting with CAP, excluding patients with hospital-
acquired pneumonia; this might further contribute to our
ﬁndings. However, our study design did not aim to calculate
the poor outcome or attributable mortality of CAP with A/H1N1
in our institution.
We conclude that in our region, the acquisition of CAP with
inﬂuenza A/H1N1 occurred in patients of Bedouin Arab origin, who
were younger females with fewer co-morbid conditions. We
believe that this and other similar ‘high-risk’ populations
worldwide must be targeted in particular by an intensive and
strict mass inﬂuenza vaccination effort.
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